33 results about "Endotoxin shock" patented technology

Medicinal compositions for treating or preventing diabetes, rheumatoid, diseases wherein inflammation should be inhibited, diseases wherein alpha-glycosidase should be inhibited, diseases wherein the synthesis of prostaglandin should be inhibited, diseases wherein endotoxin shock should be inhibited, diseases wherein the production of interleukin should be inhibited, diseases wherein the production of heme oxygenase should be induced, and diseases wherein the production of tumor necrosis factor or carcinogenesis should be inhibited, which contain as the active ingredient at least one compound selected from the group consisting of 3,6-anhydrogalactopyranose represented by formula (I), its aldehyde, its hydrate and 2-O-methylated derivatives and 2-O-sulfated derivatives thereof.

The invention relates to a novel strain, Lactobacillus fermentum strain, and a use thereof. Specifically, novel Lactobacillus fermentum PL9988, novel Lactobacillus fermentum PL9037, novel Lactobacillus fermentum PL9038, novel Lactobacillus fermentum PL9039 and novel Lactobacillus fermentum PL9040 strains, isolated from adults in a longevity village, and culture fluids thereof: have no antibiotic resistance transfer; have excellent intestinal cell adhesiveness, acid resistance and bile resistance; inhibit harmful pathogenic organisms in intestines; and have an immunity-enhancing effect, an endotoxin shock suppression effect and an antioxidant effect. In particular, Lactobacillus fermentum PL9988 strain significantly satisfies all of the above-mentioned conditions as a probiotic, and thus can be effectively used as a probiotic for intestinal health and defecation improvement and enhancement, or as a health food.

The invention discloses a medicine compound which contains muscarinic receptor antagonist and cholinesterase inhibitor. The medicine compound is used for resisting infection, particularly endotoxin shock, enhances the anti-shock effect, has significant effect, has small toxic and side effect, and overcomes the side effect that the current medicine normally causes. The invention also relates to application of the medicine compound in preparing anti-infectious, in particular to anti-endotoxin shock medicine.

The present invention relates to one kind of Chinese medicine composition for treating endotoxemia and its preparation process. The Chinese medicine composition consists of effective components prepared with capillary artemisia, cape jasmine, rhubarb, red sage, honeysuckle and other five kinds of Chinese medicinal materials in certain weight proportion, and pharmaceutically acceptable carrier. The Chinese medicine composition is used in treating endotoxemia and various diseases with endotoxemia complication, and has especially high curative effect on endotoxin induced endotoxin shock and multiple organ incompetence.

The invention discloses natural anti-inflammatory polypeptide cecropin-TY1 extracted from salivary glands of Tabancus yao. The natural anti-inflammatory polypeptide cecropin-TY1 comprises 39 amino acids, the carbon tail end is amidated, the molecular weight is 3970.22 Dalton, the isoelectric point is 11.17, the amino acid sequence is SEQ ID: 1, and all the amino acids are L-type. The natural anti-inflammatory polypeptide cecropin-TY1 has the characteristics of small molecular weight, remarkable anti-inflammatory effect and low cytotoxicity, has wide application prospects in anti-inflammatory drugs, drugs for treating septicopyemia and endotoxin shock caused by bacterial infection, veterinary drugs, animal feed and cosmetics and is particularly applied to inhibiting lipopolysaccharide induced macrophages from generating nitric oxide, inhibiting lipopolysaccharide induced macrophages from generating inflammatory cell factors, inhibiting a lipopolysaccharide induced inflammation signal path as well as neutralizeing the endotoxin.

The invention discloses application of epoxydiene taken as an inhibitor of proinflammatory mediators, and relates to a compound, namely the epoxydiene, in particular to application of the epoxydiene taken as the inhibitor of the proinflammatory mediators in medical field. The invention provides the application of the epoxydiene taken as the inhibitor of the proinflammatory mediators, in particular application in preparing a medicament for treating inflammatory diseases mediated by the proinflammatory mediators such as endotoxin shock and the like, and application in preparing a medicament for treating inflammatory diseases mediated by the proinflammatory mediators such as rheumatoid arthritis and the like. A pharmacological experiment proves that the epoxydiene has important adjustment effect on the processes of inflammations by inhibiting the expression of a plurality of the proinflammatory mediators, and can be used for preparing anti-inflammatory medicaments. The compound can be obtained by separating from fungus fermentation products, and can also be chemically synthesized.

The invention relates to an application of gambogic acid in preparing an inflammation inhibitor, in particular to an application of the gambogic acid in preparing medicaments for treating inflammatory factor mediated inflammatory diseases such as endotoxin shock and the like. The gambogic acid has a chemical formula of C38H44O8 and a molecular weight of 628.75, and can be used for preparing the medicaments for treating the inflammatory factor mediated inflammatory diseases such as endotoxin shock and the like, wherein the inflammatory diseases comprise rheumatic arthritis, inflammatory bowel disease, neurodegenerative disease, septic shock and the like. Approved by pharmacological experiments, the gambogic acid can effectively inhibit inflammatory factors such as tumor necrosis factor (TNFalpha), interleukin 6 (IL-6) and nitric oxide (NO), and can be used as an inflammation inhibitor for preparing the medicaments for treating the inflammatory factor mediated inflammatory diseases such as rheumatic arthritis, inflammatory bowel disease, neurodegenerative disease, septic shock and the like.

The invention relates to a novel strain, Lactobacillus fermentum strain, and a use thereof. Specifically, novel Lactobacillus fermentum PL9988, novel Lactobacillus fermentum PL9037, novel Lactobacillus fermentum PL9038, novel Lactobacillus fermentum PL9039 and novel Lactobacillus fermentum PL9040 strains, isolated from adults in a longevity village, and culture fluids thereof: have no antibiotic resistance transfer; have excellent intestinal cell adhesiveness, acid resistance and bile resistance; inhibit harmful pathogenic organisms in intestines; and have an immunity-enhancing effect, an endotoxin shock suppression effect and an antioxidant effect. In particular, Lactobacillus fermentum PL9988 strain significantly satisfies all of the above-mentioned conditions as a probiotic, and thus can be effectively used as a probiotic for intestinal health and defecation improvement and enhancement, or as a health food.

The invention provides the use of icraiin in preparing medicament for treating or preventing impairment caused by bacterial infection, more specifically for treating septicemia, endotoxemia and endotoxin shock. The invention also relates to the use of icraiin in preparing medicament for enhancing curative effects of antibiotics.

A method of treating and protecting a subject from endotoxin shock by administering a composition including hydrogen, releasing hydrogen in the subject, and down-regulating production of TNF-α and IL-6. A method of treating inflammation in a subject. A method of suppressing hydroxyl radical in a subject. A method of treating inflammation in a subject. A method of reducing the basal level of phosphorylation of MAPKs in non-stimulated monocyte lineage cells in a subject. Methods of performing drug screen tests for compounds that can treat the above conditions. A diagnostic method for diagnosing patients with diseases caused by the MAPK pathway.

The invention relates to tumor necrosis factor-alpha polypeptide inhibitors and application thereof. The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The invention relates to matrix metal proteinase-2 polypeptide inhibitors and application thereof. The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Asp-Asn-Phe-Ser-His-Thr which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The invention relates to biological medicines, in particular to an application of chitosan oligosaccharide in preparation of medicines for preventing and treating endotoxemia / bacteremia. The chitosan oligosaccharide can inhibit the secretion of inflammatory factors to prevent and treat endotoxin shock, i.e. the chitosan oligosaccharide can be further used for preparing medicines for preventing and treating endotoxemia. In the invention, the cell experiment shows that the chitosan oligosaccharide can inhibit the secretion of inflammatory cytokines caused by lipopolysaccharide (LPS). The animal experiment shows that the chitosan oligosaccharide can obviously improve the survival rate of a mouse with endotoxemia, inhibit the secretion of inflammatory factors TNF (tumor necrosis factor)-alpha of the mouse and inhibit the secretion of inflammatory factors IL-1beta of a macrophage strain RAW264.7 of the mouse.

The invention relates to the field of drugs and particularly relates to a polypeptide capable of activating natural killer T cells, inhibiting matrix metalloproteinases-2 and relieving destruction of acute inflammatory reaction to an organism. The polypeptide has the sequence as follows: RQQQEATRPRTAAANGLMQT which is a brand new sequence. The polypeptide can be used for inhibiting the activity of matrix metalloproteinases-2 in vitro and increasing the survival rate of endotoxin shock rats in an in-vivo test so as to have a potential novel drug development value.

The present invention relates to one kind of Chinese medicine composition for treating endotoxemia and its preparation process. The Chinese medicine composition consists of effective components prepared with capillary artemisia, cape jasmine, rhubarb, red sage, honeysuckle and other five kinds of Chinese medicinal materials in certain weight proportion, and pharmaceutically acceptable carrier. TheChinese medicine composition is used in treating endotoxemia and various diseases with endotoxemia complication, and has especially high curative effect on endotoxin induced endotoxin shock and multiple organ incompetence.

The invention relates to tumor necrosis factor-alpha polypeptide inhibitors and application thereof. The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The invention relates to a preparation method of the antipyretic and antiviral active part of the traditional Chinese medicine compound Reduning injection and its application in the preparation of antiviral medicine or antipyretic medicine. The preparation method disclosed by the invention adopts macroporous adsorption resin column chromatographic separation technology; and uses various chemical component separation methods and modern spectroscopic analysis means to separate and identify the chemical components of the active part. The active part in the present invention can significantly prolong the survival time of the stress mice infected with the influenza A (H1N1) FMI strain in vivo, reduce the death rate of the mice, and have a good antipyretic effect on the fever of the endotoxin shock mice induced by LPS. Therefore, Reduning injection and its active parts have good antipyretic and antiviral effects.

The invention discloses the application of mycoepoxydiene nicotinic acids derivatives in the preparation process of pro-inflammatory mediator inhibitors, and relates to the mycoepoxydiene nicotinic acids derivatives 4-NDM (4-N Dodecyl Mercaptan). The provided application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of the pro-inflammatory mediator inhibitors particularly relates to the application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of drugs that are used for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors. The molecular formula of the mycoepoxydiene nicotinic acids derivatives is C19H19NO4. Pharmacology experiments prove that the mycoepoxydiene nicotinic acids derivatives can effectively inhibit the expression of the inflammatory factors such as tumor necrosis factor (TNF-Alpha), interleukin 6 (IL-6) and nitric monoxide (NO). The mycoepoxydiene nicotinic acids derivatives can be used for preparing the pro-inflammatory mediator inhibitors, especially, the mycoepoxydiene nicotinic acids derivatives can be used for preparing the drugs for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors.

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.

The invention discloses the application of mycoepoxydiene nicotinic acids derivatives in the preparation process of pro-inflammatory mediator inhibitors, and relates to the mycoepoxydiene nicotinic acids derivatives 4-NDM (4-N Dodecyl Mercaptan). The provided application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of the pro-inflammatory mediator inhibitors particularly relates to the application of the mycoepoxydiene nicotinic acids derivatives in the preparation process of drugs that are used for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors. The molecular formula of the mycoepoxydiene nicotinic acids derivatives is C19H19NO4. Pharmacology experiments prove that the mycoepoxydiene nicotinic acids derivatives can effectively inhibit the expression of the inflammatory factors such as tumor necrosis factor (TNF-Alpha), interleukin 6 (IL-6) and nitric monoxide (NO). The mycoepoxydiene nicotinic acids derivatives can be used for preparing the pro-inflammatory mediator inhibitors, especially, the mycoepoxydiene nicotinic acids derivatives can be used for preparing the drugs for treating inflammatory diseases such as endotoxin shocks which are mediated by inflammatory factors.

The invention discloses an siRNA for silencing the expression of a Rongchang pig CD14. Firstly, a porcine alveolar macrophage of a CD14-enhanced green fluorescent protein (EGFP) fusion protein for stably expressing a Rongchang pig CD14 gene is established; next, four siRNAs having different loci and targeting the CD 14 gene are synthesized; then, the four siRNAs are transfected into a CD14-EGFP stable cell line by applying an efficient transfection reagent; and finally, the siRNAs capable of efficiently inhibiting the expression of the Rongchang pig CD14 gene are screened, namely the siRNAs inan article 3 (669) are capable of obviously inhibiting the expression of the Rongchang pig CD14 gene, and therefore, a theoretical basis is provided for researches related to inflammatory diseases caused by treating endotoxin shock, endoxemia and gram-negative bacteria by targeting the Rongchang pig CD14 gene.

The invention relates to the field of medicine, and particularly relates to polypeptides capable of inhibiting matrix metal proteinase-2 and tumor necrosis factor liberase and relieving damage of acute inflammation response on organisms. The sequence of the polypeptide is Pro-Thr-Thr-Asn-Arg which is a brand-new sequence. The inhibitors can inhibit the activities of the matrix metal proteinase-2 and tumor necrosis factor liberase in vitro on the 1 micromole level, and increase the survival rate of endotoxin shock mice in an in-vivo test, thereby having potential new drug development value.

The present invention provides the application of icariin in the preparation, treatment or prevention of damage caused by bacterial infection, and specifically relates to its application in the prevention or treatment of sepsis, endotoxemia and endotoxin shock caused by damage caused by bacterial infection . The invention also relates to its application in medicines for enhancing the curative effect of antibiotics.

The invention relates to the field of drugs and particularly relates to a polypeptide capable of activating natural killer T cells, inhibiting matrix metalloproteinases-9 and relieving destruction of acute inflammatory reaction to an organism. The polypeptide has the sequence as follows: VVHPLSSARWGGRR which is a brand new sequence. The polypeptide can be used for inhibiting the activity of matrix metalloproteinases-2 in vitro on the level of 1 micromole and increasing the survival rate of endotoxin shock rats in an in-vivo test so as to have a potential novel drug development value.

The invention discloses application of epoxydiene taken as an inhibitor of proinflammatory mediators, and relates to a compound, namely the epoxydiene, in particular to application of the epoxydiene taken as the inhibitor of the proinflammatory mediators in medical field. The invention provides the application of the epoxydiene taken as the inhibitor of the proinflammatory mediators, in particular application in preparing a medicament for treating inflammatory diseases mediated by the proinflammatory mediators such as endotoxin shock and the like, and application in preparing a medicament fortreating inflammatory diseases mediated by the proinflammatory mediators such as rheumatoid arthritis and the like. A pharmacological experiment proves that the epoxydiene has important adjustment effect on the processes of inflammations by inhibiting the expression of a plurality of the proinflammatory mediators, and can be used for preparing anti-inflammatory medicaments. The compound can be obtained by separating from fungus fermentation products, and can also be chemically synthesized.

The invention relates to sense oligonucleotide having a sequence complementary to a single-stranded RNA (antisense transcript) having a sequence complementary to mRNA of iNOS gene in order to control expression of iNOS (inducible nitric oxide synthase). The sense oligonucleotide of the present invention can control expression of iNOS and is useful for biological defense and treatment and prevention of diseases related to excessive production of NO, such as cancerogenesis, inflammatory disease, endotoxin shock by bacterial infection and the like.

Matrix metalloproteinase-2 polypeptide inhibitors and applications thereof. The invention relates to the field of medicine, in particular to a polypeptide capable of inhibiting matrix metalloproteinase-2 and tumor necrosis factor-releasing enzyme and reducing acute inflammatory response damage to the body. Its sequence is Asp-Asn-Phe-Ser-His-Thr, which is a brand new sequence. They can inhibit the activity of matrix metalloproteinase-2 and tumor necrosis factor releasing enzyme in vitro at the level of 1 micromolar, and increase the activity of endogenous enzymes in vivo. The survival rate of mice in toxin shock has potential value for new drug development.

The invention discloses application of nitixinone in preparation of a medicine for preventing and treating endotoxic shock diseases, and belongs to the field of biological medicines. Animal experiments prove that the nitixinone can improve the survival rate of endotoxin shock mice by inhibiting secretion of inflammatory cytokines IL-1b, IL-6 and TNF-alpha and chemotactic factors MCP-1 and the like caused by LPS exposure, so that the nitixinone has a potential value of being developed into a new generation of new-generation medicines for preventing and treating endotoxin shock, and has a wide application prospect. And a new way is provided for prevention and treatment of endotoxin shock.